Clinical Pharmacokinetics and Pharmacodynamics of Baxdrostat.

IF 2.8 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

American Journal of Cardiovascular Drugs Pub Date : 2024-12-31 DOI:10.1007/s40256-024-00713-w

Jessica Huston, Dontia Orey, Ashish Kumar, Andrew Ashchi, Andrea Ashchi, Jason Berner, Yazan Alkhouri, David Sutton, Wasim Deeb, Mohannad Bisharat, Rebecca F Goldfaden

引用次数: 0

Abstract

Patients with hypertension are at an increased risk of cardiovascular disease and death. Resistant hypertension, or hypertension that is unsuccessfully treated with multiple antihypertensive medications, further exacerbates the complications and negative outcomes for patients. A new pathway, via aldosterone synthesis inhibition, is currently being studied as a method to reduce blood pressure values in patients who are currently taking other antihypertensive medications. This review presents and discusses the current pharmacokinetic, pharmacodynamic, and clinical and scientific evidence pertaining to baxdrostat, a novel aldosterone synthase inhibitor.

查看原文本刊更多论文

巴司他的临床药代动力学和药效学。

高血压患者患心血管疾病和死亡的风险增加。顽固性高血压，或多种降压药物治疗不成功的高血压，进一步加剧了患者的并发症和负面结果。目前正在研究一种新的途径，通过醛固酮合成抑制，作为一种降低目前正在服用其他抗高血压药物的患者血压值的方法。这篇综述介绍并讨论了当前的药代动力学、药效学、临床和科学证据有关巴克斯他，一种新型醛固酮合成酶抑制剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Cardiovascular Drugs 医学-心血管系统

CiteScore

6.70

自引率

3.30%

发文量

审稿时长

>12 weeks

期刊介绍： Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents. Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations. The American Journal of Cardiovascular Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.